Aligos Therapeutics downgraded by Piper Sandler with a new price target

3/23/22 7:05:03 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Piper Sandler downgraded Aligos Therapeutics from Overweight to Neutral and set a new price target of $4.00 from $15.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALGS

Date	Price Target	Rating	Analyst
8/19/2024	$75.00	Buy	H.C. Wainwright
1/6/2023	$2.00 → $3.00	Neutral → Overweight	Piper Sandler
1/6/2023	$2.50 → $3.00	Hold → Buy	Jefferies
3/23/2022	$15.00 → $4.00	Overweight → Neutral	Piper Sandler
3/11/2022	$47.00 → $15.00	Overweight	Piper Sandler
3/11/2022	$10.00 → $11.00	Outperform	SVB Leerink
2/16/2022	$15.00 → $10.00	Outperform	SVB Leerink
1/7/2022	$30.00 → $12.00	Overweight → Neutral	JP Morgan